Furthermore, 4‐HB analogs may provide therapeutic effects in other conditions, e.g., mitochondrial disorders, since secondary CoQ deficiency due to decreased levels of CoQ biosynthetic proteins have been recently reported in various mouse models of mitochondrial diseases (Kuhl et al, 2017); or metabolic diseases due to insulin resistance since secondary CoQ deficiency due to decreased levels of CoQ biosynthetic proteins have been recently described in in vitro insulin resistance models and adipose tissue from insulin‐resistant humans (Fazakerley et al, 2018). Here, INS is linked to Other metabolic disease.